| DB ID | MyCo_2427 |
| Title | Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis |
| Year | 2014 |
| PMID | 24587262 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The protocol was approved by the appropriate institutional review boards in all participating centers, and written informed consent was obtained from all patients. |
| Site of Infection | None |
| Opportunistic invasive | Invasive/Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM+Amphotericin B |
| Biomarker Full Name | Galactomannan+Amphotericin B |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Europe, Australia and Israel |
| Cohort | The patients studied were from Protocol 150–307 of the Global Comparative Aspergillosis Study, a multicenter randomized trial conducted in Europe, Australia and Israel that compared the efficacy of VCZ versus CAB for the primary treatment of IA. Data from one hundred and forty-seven patients with proven and probable IA and who had GMI measurements performed were studied, based on the modified intention-to-treat analysis. |
| Cohort No. | 147 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is the most common opportunistic mold infection in immunocompromised patients and leads to significant morbidity and mortality. The presence of neutropenia and the concurrent use immunomodulatory agents not only hinder the ability of the host to mount an efficient inflammatory response against the pathogen but also make the monitoring of response to anti-fungal treatment difficult. Galactomannan is a distinct polysaccharide component of the Aspergillus cell wall and its quantification can serve as a surrogate marker for fungal burden. The detection of galactomannan with the Platelia Aspergillus EIA, the galactomannan index (GMI) has been adopted as a criterion in the diagnosis of IA and it has also been suggested that serial determination of serum GMI may be useful for monitoring the response to treatment. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus; Bio‐Rad laboratories, Marnes‐la- Coquette, France |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
